Boston Scientific Expects Synergy To Dominate Drug-Eluting Stents In US
Boston Scientific wants to expand the lead against other stents used by interventional cardiologists with the launch of its bioabsorbable Synergy drug-eluting stent. The company expects it will become the workhorse of the industry to handle a broad range of surgeries to treat coronary artery disease.
You may also be interested in...
The company announced July 20 the start of its 30-patient, single-arm FAST study assessing its everolimus-eluting scaffold system, but executives says Boston Scientific will be closely considering whether the system warrants long-term investment, considering the promise of its Synergy stent.
The firm's FDA submission for the first-in-class bioresorbable vascular scaffold was completed in the second quarter, a spokesman said. That appears to be ahead of a prior estimate to submit by the end of 2015.
The US agency’s Center for Devices and Radiological Health is assembling an in-person advisory committee meeting in early June, the first since the COVID-19 pandemic began. The goal is to discuss the approval of an implant device to treat the natural aging of the eye.